본문 바로가기 주메뉴 바로가기
  • HOME
  • Public Relations
  • GC Cell News

GC Cell News

GC Cell Becomes a CDMO Specializing in Cell Therapeutics
2021-03-02
GC Cell Becomes a CDMO Specializing in Cell Therapeutics
GC Cell, the company specializing in cell therapy, obtained the "Approval of Management Businesses for Human Cells, etc." from the Ministry of Food and Drug Safety on February 26th.
The approval of the human cell management business was newly introduced by the ‘Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety and Support Act’. A company needs to obtain the Approval of Management Businesses for Human Cells in order to collect, process, and supply human cells, which are raw materials for advanced biopharmaceuticals.
This approval on management businesses for human cells allows GC Cell to gain an advantage by establishing the business framework of a CDMO(Contract Development and Mmanufacturing Oorganization) for cell therapeutics faster than any other advanced biopharmaceuticals manufacturers in Korea. In particular, the cGMP-level facilities and high-tech production equipment, which is optimized for the production of cell therapeutics, and the cell center with advanced management and production systems will be the growth engine of GC Cell in the future.
GC Cell is sufficient enough to be able to compete in the CDMO business specializing in cell therapeutics because they acquired the know-how through the approval, production, and sales of cell therapy products accumulated since 2007. Based on this, we will present a new standard for the rapidly growing CDMO business in the future.
Next
GC Cell Completes pct for entry into the global market
Previous
GC Cell Acquired an IND Approval of a Phase-III Clinical Trial for Immuncell-LC Injection Targeting Pancreatic Cancer